search
Back to results

Oral Antibiotics After Obstetric Perineal Tear (REPAIR)

Primary Purpose

Obstetric Trauma, Infections, Wound Dehiscence

Status
Recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Placebo
Bioclavid (Amoxicillin and Clavulanic acid)
Sponsored by
Hanna Jangö
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstetric Trauma focused on measuring obstetric tear, women's health, antibiotics, infection, wound dehiscence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Danish speaking women above 18 years Second degree perineal tear and/or episiotomy Suturing of obstetric tear at Herlev Hospital Exclusion Criteria: Allergies to the treatment. Women who end up with a cesarean-section, including those who have obstetric tears that require stitching or have had an episiotomy Women who receive antibiotics intra- or postpartum for other reasons.

Sites / Locations

  • Maternaty ward, Herlev HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Antibiotics (bioclavid)

Arm Description

The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly variating block sizes. Women in the placebo arm will get 3 calcium tablets to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery.

The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly varying block sizes. Women in the antibiotic arm will get 3 tablets bioclavid (amoxicillin and Clavulanic acid) to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery.

Outcomes

Primary Outcome Measures

Infection in the obstetric tear
We use the REEDA criteria for estimating of this outcome: Redness, Edema, Ecchymosis, Discharge, Approximation.
Wound dehiscence
We will measure the amount of dehiscence and if above 5 mm it will be diagnoses as a wound dehiscence.

Secondary Outcome Measures

Pain
Questionnaire with use of Visual Analogue Scale (VAS) from 1-10 with 10 being the worst pain.
Sexual problems
Questionnaire
Body image
Questionnaire -
Number of patients with prolapse
Gynaecological examination
Prolapse
Questionnaire (asking if the women have had symptoms of prolapse)
incontinence
Questionnaire

Full Information

First Posted
March 29, 2023
Last Updated
April 26, 2023
Sponsor
Hanna Jangö
Collaborators
Region Hovedstadens Apotek
search

1. Study Identification

Unique Protocol Identification Number
NCT05830162
Brief Title
Oral Antibiotics After Obstetric Perineal Tear
Acronym
REPAIR
Official Title
Oral Antibiotics to Prevent Infection and Wound Dehiscence After Obstetric Perineal Tear - a Double-blinded Placebo Controlled Randomized Trail
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 21, 2023 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Hanna Jangö
Collaborators
Region Hovedstadens Apotek

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to investigate if 3 dose of oral antibiotics administrated the first day after a vaginal delivery with a second degree obstetric tear will decrease the risk of infection and/or wound dehiscence compared to women with 3 doses of placebo treatment.
Detailed Description
Background: Obstetric tear occurs in more than 90% of nulliparous women and up to 25% subsequently experience wound dehiscence and/or infection. Some data shows that intravenous antibiotics given during delivery reduces this risk. It is unknown if oral antibiotics given after delivery can reduce the risk of wound dehiscence or infection. The study-goupe want to investigate whether three doses of antibiotics (amoxicillin 500 mg / clavulanic acid 125 mg) given after delivery can reduce the risk of wound dehiscence and infection. Methods: The investigators will perform a randomized, controlled, double-blinded study and plan to include 221 women in each arm with allocation 1:1 in relation to the randomization. The study is carried out at Department of Obstetrics & Gynecology, Herlev University Hospital, Copenhagen, Denmark. The women will be included after delivery if they have had a second-degree tear or episiotomy. The first tabelt has to be taken with in 6 hours from the delivery. After inclusion, the women will have a clinical follow up visit after one week. The tear and healing will be evaluated regarding infection and/or dehiscence. The women will again be invited for a one year clinical examination including ultrasound. Questionaries exploring symptoms related to the vaginal tear and possible complications will be answered at both visits. The primary outcome is wound dehiscence and/or wound infection, which will be calculated using χ2-tests to compare groups. Secondary outcomes are variables that relate to wound healing, for example pain, use of painkillers, need for further follow-up, as well as other outcomes that may be related to the birth or healing process; urinary or anal incontinence, symptoms of prolapse, female body image and sexual problems. Discussion: Reducing the risk of wound dehiscence and/or infection would decrease the number of control visits, prevent the need for longer antibiotic treatment and possibly also decrease both short-term and long-term symptoms. This would be of great importance since the period after a delivery is a crucial time for the whole family.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstetric Trauma, Infections, Wound Dehiscence
Keywords
obstetric tear, women's health, antibiotics, infection, wound dehiscence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
442 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly variating block sizes. Women in the placebo arm will get 3 calcium tablets to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery.
Arm Title
Antibiotics (bioclavid)
Arm Type
Experimental
Arm Description
The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly varying block sizes. Women in the antibiotic arm will get 3 tablets bioclavid (amoxicillin and Clavulanic acid) to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
Intervention Type
Drug
Intervention Name(s)
Bioclavid (Amoxicillin and Clavulanic acid)
Intervention Description
We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
Primary Outcome Measure Information:
Title
Infection in the obstetric tear
Description
We use the REEDA criteria for estimating of this outcome: Redness, Edema, Ecchymosis, Discharge, Approximation.
Time Frame
Infection will be evaluated 1-2 weeks after the delivery.
Title
Wound dehiscence
Description
We will measure the amount of dehiscence and if above 5 mm it will be diagnoses as a wound dehiscence.
Time Frame
Wound dehiscence will be evaluated 1-2 weeks after the delivery
Secondary Outcome Measure Information:
Title
Pain
Description
Questionnaire with use of Visual Analogue Scale (VAS) from 1-10 with 10 being the worst pain.
Time Frame
9-12 months after delivery.
Title
Sexual problems
Description
Questionnaire
Time Frame
9-12 months after delivery.
Title
Body image
Description
Questionnaire -
Time Frame
9-12 months after delivery.
Title
Number of patients with prolapse
Description
Gynaecological examination
Time Frame
9-12 months after delivery.
Title
Prolapse
Description
Questionnaire (asking if the women have had symptoms of prolapse)
Time Frame
9-12 months after delivery.
Title
incontinence
Description
Questionnaire
Time Frame
9-12 months after delivery.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Danish speaking women above 18 years Second degree perineal tear and/or episiotomy Suturing of obstetric tear at Herlev Hospital Exclusion Criteria: Allergies to the treatment. Women who end up with a cesarean-section, including those who have obstetric tears that require stitching or have had an episiotomy Women who receive antibiotics intra- or postpartum for other reasons.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanna M Jangö, MD, PhD
Phone
38381612
Email
hanna.margareta.jangoe@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Kathrine Perslev, MD, PhD student
Phone
38696799
Email
kathrine.perslev@regionh.dk
Facility Information:
Facility Name
Maternaty ward, Herlev Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanna M Jangö, MD
Phone
+45 38381612
Email
hanna.margareta.jangoe@regionh.dk
First Name & Middle Initial & Last Name & Degree
Kathrine Perslev, MD
Phone
+45 38696799
Email
kathrine.perslev@regionh.dk

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Oral Antibiotics After Obstetric Perineal Tear

We'll reach out to this number within 24 hrs